Literature DB >> 24267474

American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

Jonathan P Terdiman1, Claudia B Gruss, Joel J Heidelbaugh, Shahnaz Sultan, Yngve T Falck-Ytter.   

Abstract

Entities:  

Keywords:  AGA; American Gastroenterological Association Institute; CD; Crohn's disease; Development and Evaluation; GRADE; Grading of Recommendations Assessment; PICO; TNF; and outcome; comparator; intervention; population; tumor necrosis factor

Mesh：

Substances：

Year:  2013        PMID： 24267474     DOI： 10.1053/j.gastro.2013.10.047

Source DB:  PubMed          Journal:  Gastroenterology        ISSN： 0016-5085            Impact factor:   22.682


× No keyword cloud information.
  85 in total

1.  Risks of Infection among the Older Inflammatory Bowel Disease Patients.

Authors:  Christina Y Ha
Journal:  Curr Treat Options Gastroenterol       Date:  2014-09

2.  Early combined immunosuppression may be effective and safe in older patients with Crohn's disease: post hoc analysis of REACT.

Authors:  Siddharth Singh; Larry W Stitt; Guangyong Zou; Reena Khanna; Parambir S Dulai; William J Sandborn; Brian G Feagan; Vipul Jairath
Journal:  Aliment Pharmacol Ther       Date:  2019-03-19       Impact factor: 8.171

3.  Payer Perspective of the American Academy of Sleep Medicine Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia.

Authors:  Michael J Sateia; William C Sherrill; Carolyn Winter-Rosenberg; Jonathan L Heald
Journal:  J Clin Sleep Med       Date:  2017-02-15       Impact factor: 4.062

Review 4.  Ustekinumab: A Review in Moderate to Severe Crohn's Disease.

Authors:  Yvette N Lamb; Sean T Duggan
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

5.  Bridging Gaps in Evidence-based Clinical Practice in Inflammatory Bowel Diseases: Observational Comparative Effectiveness Research for the Win.

Authors:  Frank I Scott; Siddharth Singh
Journal:  Clin Gastroenterol Hepatol       Date:  2019-01-07       Impact factor: 11.382

Review 6.  Myeloid disorders after autoimmune disease.

Authors:  Prajwal C Boddu; Amer M Zeidan
Journal:  Best Pract Res Clin Haematol       Date:  2019-02-07       Impact factor: 3.020

7.  The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model.

Authors:  Frank I Scott; Ravy K Vajravelu; Meenakshi Bewtra; Ronac Mamtani; Dale Lee; David S Goldberg; James D Lewis
Journal:  Clin Gastroenterol Hepatol       Date:  2014-08-10       Impact factor: 11.382

Review 8.  Immunology of inflammatory bowel disease and molecular targets for biologics.

Authors:  Maneesh Dave; Konstantinos A Papadakis; William A Faubion
Journal:  Gastroenterol Clin North Am       Date:  2014-09       Impact factor: 3.806

9.  Resource use and cost of care with biologicals in Crohn's disease in South Africa: a retrospective analysis from a payer perspective.

Authors:  Jacqui Miot; Susan Smith; Niri Bhimsan
Journal:  Int J Clin Pharm       Date:  2016-04-27

10.  Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.

Authors:  Heather Catt; Keith Bodger; Jamie J Kirkham; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.